Publications

Complete List of Published Work in My Bibliography:
https://www.ncbi.nlm.nih.gov/myncbi/marty.mayo.1/bibliography/public/

Lengel HB, Mastrogiacomo B, Connolly JG, Tan KS, Liu Y, Fick CN, Dunne EG, He D, Lankadasari MB, Satravada BA, Sun Y, Kundra R, Fong C, Smith S, Riely GJ, Rudin CM, Gomez DR, Solit DB, Berger MF, Li BT, Mayo MW, Matei I, Lyden DC, Adusumilli PS, Schultz N, Sanchez-Vega F, Jones DR. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell. 2023. r8:S1535-6108(23)00091-0. doi: 10.1016/j.ccell.2023.03.018. Epub ahead of print. PMID: 37084736.

Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW*. Replicative Instability Drives Cancer Progression. Biomolecules. 2022 doi: 10.3390/biom12111570. PMCID: PMC9688014. Selected as Editor’s Choice

Liu Y, Chudgar N, Mastrogiacomo B, He D, Lankadasari MB, Bapat S, Jones GD, Sanchez-Vega F, Tan KS, Schultz N, Mukherjee S, Offit K, Bao Y, Bott MJ, Rekhtman N, Adusumilli PS, Li BT, Mayo MW, Jones DR. A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fos. Sci Transl Med. 2022 Oct 5;14(665):eabo1050. doi: 10.1126/scitranslmed.abo1050. Epub 2022 Oct 5. PMID: 36197962; PMCID: PMC9926934.

Sessions DT, Kim KB, Kashatus JA, Churchill N, Park KS, Mayo MW, Sesaki H, Kashatus DF. Opa1 and Drp1 reciprocally regulate cristae morphology, ETC function, and NAD+ regeneration in KRas-mutant lung adenocarcinoma. Cell Rep. 2022 Dec 13;41(11):111818. doi: 10.1016/j.celrep.2022.111818. PMID: 36516772.

Morris BB, Wages NA, Grant PA, Stukenberg PT, Gentzler RD, Hall RD, Akerley WL, Varghese TK, Arnold SM, Williams TM, Coppola V, Jones DR, Auble DT, and Mayo MW*. 2021. MYBL2 drives error-prone DNA repair and poor outcomes in lung adenocarcinoma. Front. Oncol. 2021;10:585551. PMCID: PMC7821388. Chosen as Editor’s Pick for one of the best manuscripts of 2021

Jones GD, Brandt WS, Shen R, Sanchez-Vega F, Tan KS, Martin A, Zhou J, Berger M, Solit
DB, Schultz N, Rizvi H, Liu Y, Adamski A, Chaft JE, Riely GJ, Rocco G, Bott MJ, Molena D, Ladanyi M, Travis WD, Rekhtman N, Park BJ, Adusumilli PS, Lyden D, Imielinski M, Mayo MW, Li BT, Jones DR*. 2020. A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA Surg. PMCID: PMC7758824

Caso R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, Zhou J, Jones GD, Nguyen B, Schultz
N, Connolly JG, Brandt WS, Bott MJ, Rocco G, Molena D, Isbell JM, Liu Y, Mayo MW,
Adusumilli PS, Travis WD, Jones DR*. 2020. The underlining tumor genomics of predominant histologic subtypes in lung adenocarcinoma. J Thorac Oncol. PMCID: PMC7704768

Przanowski P, Lou S, Tihagam RD, Mondal T, Conlan C, Shivange G, Saltani I, Singh C, Xing K, Morris BB, Mayo MW, Teixeira L, Lehmann-Che J, Tushir-Singh J *, Bhatnagar S.* 2020. Oncogenic TRIM37 links chemoresistance and metastatic fate in triple-negative breast cancer. Cancer Res. 2020 80:4791-4804. PMCID: PMC7731897

Saha, S, Kiran M, Kuscu C, Chatrath A, Wotton D, Mayo MW, and Dutta A*. 2020. Long noncoding RNA DRAIC inhibits prostate cancer progression by interacting with IKK to inhibit NF-κB activation. Cancer Res. PMCID: PMC7056510.

Szymura SJ, Zaemes JP, Allison DF, Clift SH, D’Innocenzi JM, Gray LG, McKenna BD, Morris BB, Bekiranov S, LeGallo RD, Jones DR, Mayo MW*. 2019. NF-κB upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small cell lung cancer. Cell Commun Signal. 18;17(1):24. doi: 10.1186/s12964-019-0335-5. PMCID: PMC6421657.